Literature DB >> 25305148

Participation in and support of clinical studies and other scientific investigations - Statement of the German Society for Pathology.

Christoph Röcken1, Heinz Höfler2, Michael Hummel3, Richard Meyermann4, Christian Zietz5, Peter Schirmacher6.   

Abstract

Clinical studies and preclinical investigations are essential in order to test new therapies and diagnostic techniques aimed at sustainable improvements in the treatment of patients. Fortunately, the number of clinical studies is continuously increasing and pathology and tissue-based research are more frequently involved. Pathologists are essential in this process and committed to support it by joining forces with our clinical partners. The investigative diagnostic technologies we apply to human cell and tissue samples and our specific expertise are essential contributions to the quality and success of preclinical investigations, clinical studies, and the implementation of results into clinical diagnostic pathology. In order to support this process, the German Society of Pathology has formulated a statement on the participation in and support of clinical studies and other scientific investigations with a special focus on tissue-based research.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Biobanking; Clinical trials; Diagnostics; Therapy; Tissue-based research; Treatment improvements

Mesh:

Year:  2014        PMID: 25305148     DOI: 10.1016/j.prp.2014.09.001

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  2 in total

1.  [Recovery of paraffin blocks and central archiving : Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma].

Authors:  M Čavčić; I Oschlies; M Fuchs; A Engert; W Klapper
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

Review 2.  Quality assurance in clinical trials--the role of pathology.

Authors:  Christoph Röcken
Journal:  Virchows Arch       Date:  2015-10-01       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.